Levodopa-carbidopa intestinal gel
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dyskinesias
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Trial Timeline
Jun 1, 2009 → Oct 1, 2012
NCT ID
NCT00360568About Levodopa-carbidopa intestinal gel
Levodopa-carbidopa intestinal gel is a phase 3 stage product being developed by AbbVie for Dyskinesias. The current trial status is completed. This product is registered under clinical trial identifier NCT00360568. Target conditions include Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01960842 | Phase 3 | Completed |
| NCT00360568 | Phase 3 | Completed |
| NCT00335153 | Phase 3 | Completed |
Competing Products
4 competing products in Dyskinesias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AFQ056 | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| AQW051 + AQW051 + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |